Harvey Investment Co. LLC Has $1.37 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Harvey Investment Co. LLC decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 61.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,661 shares of the medical instruments supplier’s stock after selling 9,194 shares during the quarter. Harvey Investment Co. LLC’s holdings in Becton, Dickinson and Company were worth $1,365,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of BDX. Livelsberger Financial Advisory bought a new stake in Becton, Dickinson and Company in the 3rd quarter valued at approximately $26,000. Sound Income Strategies LLC lifted its position in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company in the second quarter worth $45,000. Abound Wealth Management boosted its holdings in Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares during the last quarter. Finally, Chilton Capital Management LLC grew its position in Becton, Dickinson and Company by 1,233.3% in the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 185 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Trading Up 0.2 %

BDX stock opened at $240.92 on Thursday. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $262.23. The stock has a market cap of $69.63 billion, a price-to-earnings ratio of 52.98, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42. The company has a fifty day moving average price of $237.33 and a two-hundred day moving average price of $235.16. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. During the same period in the prior year, the firm earned $2.96 EPS. The business’s revenue was up 2.3% on a year-over-year basis. Equities analysts anticipate that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of recent research reports. Raymond James reduced their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Evercore ISI increased their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Finally, Stifel Nicolaus raised their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.